Salix gains new rights as rifaximin deal with Alfa restructured
This article was originally published in Scrip
Salix Pharmaceuticals is again seeking new lines of revenue from its top-selling product, Xifaxan (rifaximin) for traveller's diarrhoea and hepatic encephalopathy, most recently by renegotiating with Alfa Wasserman Salix's North American rights to rifaximin to include an extended intestinal release (EIR) formulation in gastrointestinal and respiratory indications, including Crohn's disease, for $10 million upfront.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.